Friday 6 November 2026 Export AMRX’s income statement to Excel — free account

AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.

Revenue: +9.96%
EPS: +267.0%
Free cash flow: −50.9%
Total debt: +23.8%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

19.90 0.45 +2.31%

Follow AMRX

Alert me

Market cap: $6.8B
P/E: 36.9×
Fwd P/E: 44.2×
Dividend yield: —
F-score: 7/9
Altman Z: 1.94
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

AMNEAL PHARMACEUTICALS, INC. 10-Q filed Nov 6, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed Nov 6, 2025 · accepted 4:16 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov